Key result
Dickkopf-3 fails to provide diagnostic or prognostic value in acute heart failure.
Why the study?
Evidence from small cohorts implicated Dickkopf-3 (DKK3) as a potential heart failure biomarker, and renal function reflected by eGFR may modulate its diagnostic and prognostic performance in acute heart failure.
Does Dickkopf-3 (DKK3) provide diagnostic and prognostic utility in patients presenting to the emergency department with acute dyspnea and suspected acute heart failure across different strata of renal function?
Cohort (n=1,176)
Does Dickkopf-3 (DKK3) provide diagnostic and prognostic utility in patients presenting to the emergency department with acute dyspnea and suspected acute heart failure across different strata of renal function?
Dickkopf-3 (DKK3) does not provide diagnostic or 720-day prognostic utility in patients presenting to the emergency department with acute heart failure, regardless of renal function.
DKK3 should not guide acute HF diagnosis or prognosis in the ED; challenges small-cohort biomarker hypotheses and leaves its role open.
Background Evidence from small cohorts has implicated Dickkopf-3 (DKK3) as a potential biomarker in heart failure, while renal function, as reflected by estimated glomerular filtration rate (eGFR), may modulate its performance in acute heart failure (AHF). Aim To assess the diagnostic and prognostic utility of DKK3 in AHF patients presenting with acute dyspnea to the emergency department (ED) with particular consideration of renal function. Methods DKK3 was available in 1.176 patients presenting with acute dyspnea to the ED. Diagnostic accuracy for AHF was evaluated using the area under the receiver operating characteristic curve (AUC). Prognostic outcomes were 720-day all-cause mortality and a composite of mortality or AHF rehospitalization. Analyses were stratified by eGFR.DKK3 levels were compared across eGFR strata (<30, 30–59, ≥60 mL/min/1.73 m²) using log-scaled boxplots and Kruskal–Wallis tests. Results A total of 604 patients (51%) had an adjudicated final diagnosis of AHF. Although DKK3 concentrations were higher in AHF patients, values did not differ significantly when compared to patients with different causes of dyspnea (438 vs. 337 pg/mg creatinine; p=0.17). DKK3 correlated weakly with NT-proBNP (ρ=0.15; p<0.0001) and lacked diagnostic discrimination across eGFR strata( ≥60=AUC 0.53; 30–59=AUC 0.5; <30=AUC 0.51 figure 1). Those with eGFR <30 exhibited significantly higher DKK3 levels on day 2, day 6, and at discharge(figure 2). Median DKK3 levels did not differ between patients with and without adverse outcomes at 720 days (all-cause mortality p=0.4; composite: p=0.8), and prognostic accuracy remained minimal (all-cause mortality: AUC 0.49 95% CI 0.45–0.52; composite endpoint: AUC 0.5 95% CI 0.46–0.53). DKK3 was neither an independent predictor for all-cause mortality nor the combined endpoint (p=0.2 and p=0.06, respectively) in Cox regression models. Conclusions In our cohort, DKK3 lacked diagnostic and prognostic utility in acute heart failure, irrespective of renal function. Diagnostic accuracy of DKK3 Changes in DKK3 concentrations over time
No takes yet. Share an insight, caveat, or question.
Dan et al. (2026) conducted a cohort in Acute heart failure / Acute dyspnea (n=1,176). Dickkopf-3 (DKK3) vs. Non-AHF causes of dyspnea / across eGFR strata (<30, 30-59, ≥60 mL/min/1.73 m²) was evaluated on Diagnostic accuracy for AHF, and 720-day all-cause mortality and a composite of mortality or AHF rehospitalization (AUC 0.49, 95% CI 0.45-0.52, p=0.4). Dickkopf-3 lacked diagnostic discrimination for acute heart failure across eGFR strata (AUC 0.50-0.53) and prognostic accuracy for 720-day mortality (AUC 0.49, 95% CI 0.45-0.52; p=0.4).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: